Legal Representation
Attorney
Tamara A. Miller
USPTO Deadlines
Next Deadline
1890 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-09-10)
Due Date
September 10, 2030
Grace Period Ends
March 10, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
20 events| Date | Code | Type | Description |
|---|---|---|---|
| Mar 12, 2025 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Sep 10, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Sep 10, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jun 25, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jun 25, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jun 5, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| May 20, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 16, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| May 16, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| May 16, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 14, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| May 14, 2024 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| May 14, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| May 14, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Feb 19, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Feb 19, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Feb 19, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Feb 14, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Jan 9, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Nov 24, 2023 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 042
Scientific and technological services, namely, scientific research in the field of medicine and pharmaceuticals; scientific and technological services, namely, testing and analysis of medicine and pharmaceuticals; scientific and technological services, namely, research and development of technology in the field of medicine and pharmaceuticals; research and development and consultation related thereto in the field of antibody development; scientific research services, namely, antibody engineering for analytical and clinical purposes; antibody engineering; custom design and engineering of antibodies; research in the field of antibodies, using a platform of biological research tools and techniques; providing an online database containing antibody information for research purposes
First Use Anywhere:
May 27, 2017
First Use in Commerce:
May 27, 2017
Classification
International Classes
042